Rituximab, a first-line targeted therapy agent for DLBCL, not only improves clinical outcomes but also induces ferroptosis in OCI-LY1 cells by suppressing the SLC7A11/GPX4 axis, depleting GSH, and increasing MDA levels [156]. This evidence concerns the gene GPX4 and diffuse large B-cell lymphoma.